Cargando…

Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis

BACKGROUND: Breast cancer lung metastasis occurs in more than 60% of all patients with breast cancer, and most of those afflicted by it eventually die of recurrence. The tumor microenvironment plays vital roles in metastasis. Modulating the tumor microenvironment via multiple pathways could efficien...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Xie, Xingmei, Hou, Xuefeng, Shen, Junyi, Shi, Jiangpei, Chen, Haizhen, He, Yuanzhi, Wang, Zhi, Feng, Nianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260741/
https://www.ncbi.nlm.nih.gov/pubmed/32473632
http://dx.doi.org/10.1186/s12951-020-00638-x
_version_ 1783540381645799424
author Liu, Ying
Xie, Xingmei
Hou, Xuefeng
Shen, Junyi
Shi, Jiangpei
Chen, Haizhen
He, Yuanzhi
Wang, Zhi
Feng, Nianping
author_facet Liu, Ying
Xie, Xingmei
Hou, Xuefeng
Shen, Junyi
Shi, Jiangpei
Chen, Haizhen
He, Yuanzhi
Wang, Zhi
Feng, Nianping
author_sort Liu, Ying
collection PubMed
description BACKGROUND: Breast cancer lung metastasis occurs in more than 60% of all patients with breast cancer, and most of those afflicted by it eventually die of recurrence. The tumor microenvironment plays vital roles in metastasis. Modulating the tumor microenvironment via multiple pathways could efficiently prevent or inhibit lung metastasis. Silibinin and cryptotanshinone are natural plant products that demonstrate anti-metastasis effects and modulate the tumor microenvironment via different pathways. However, they have poor aqueous solubility, membrane permeability, and oral bioavailability. Oral drug administration may help improve the quality of life and compliance of patients with breast cancer, primarily under long-term and/or follow-up therapy. Herein, we developed poly-N-(2-hydroxypropyl) methacrylamide (pHPMA)-coated wheat germ agglutinin-modified lipid-polymer hybrid nanoparticles, co-loaded with silibinin and cryptotanshinone (S/C-pW-LPNs). We assessed their oral bioavailability, and evaluated their anti-metastasis efficacy in a 4T1 breast cancer tumor-bearing nude mouse model. RESULTS: An in vitro mucus diffusion study revealed that pHPMA enhanced W-LPN mucus penetration. After oral administration, pHPMA enhanced nanoparticle distribution in rat jejunum and substantially augmented oral bioavailability. S/C-W-LPNs markedly increased 4T1 cell toxicity and inhibited cell invasion and migration. Compared to LPNs loaded with either silibinin or cryptotanshinone alone, S/C-pW-LPNs dramatically slowed tumor progression in 4T1 tumor-bearing nude mice. S/C-pW-LPNs presented with the most robust anti-metastasis activity on smooth lung surfaces and mitigated lung metastasis foci. They also downregulated tumor microenvironment biomarkers such as CD31, TGF-β1, and MMP-9 that promote metastasis. CONCLUSIONS: Silibinin- and cryptotanshinone-co-loaded pW-LPNs efficiently penetrate intestinal barriers, thereby enhancing the oral bioavailability of the drug loads. These nanoparticles exhibit favorable anti-metastasis effects in breast cancer-bearing nude mice. Hence, S/C-pW-LPNs are promising oral drug nanocarriers that inhibit breast cancer lung metastasis.
format Online
Article
Text
id pubmed-7260741
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72607412020-06-07 Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis Liu, Ying Xie, Xingmei Hou, Xuefeng Shen, Junyi Shi, Jiangpei Chen, Haizhen He, Yuanzhi Wang, Zhi Feng, Nianping J Nanobiotechnology Research BACKGROUND: Breast cancer lung metastasis occurs in more than 60% of all patients with breast cancer, and most of those afflicted by it eventually die of recurrence. The tumor microenvironment plays vital roles in metastasis. Modulating the tumor microenvironment via multiple pathways could efficiently prevent or inhibit lung metastasis. Silibinin and cryptotanshinone are natural plant products that demonstrate anti-metastasis effects and modulate the tumor microenvironment via different pathways. However, they have poor aqueous solubility, membrane permeability, and oral bioavailability. Oral drug administration may help improve the quality of life and compliance of patients with breast cancer, primarily under long-term and/or follow-up therapy. Herein, we developed poly-N-(2-hydroxypropyl) methacrylamide (pHPMA)-coated wheat germ agglutinin-modified lipid-polymer hybrid nanoparticles, co-loaded with silibinin and cryptotanshinone (S/C-pW-LPNs). We assessed their oral bioavailability, and evaluated their anti-metastasis efficacy in a 4T1 breast cancer tumor-bearing nude mouse model. RESULTS: An in vitro mucus diffusion study revealed that pHPMA enhanced W-LPN mucus penetration. After oral administration, pHPMA enhanced nanoparticle distribution in rat jejunum and substantially augmented oral bioavailability. S/C-W-LPNs markedly increased 4T1 cell toxicity and inhibited cell invasion and migration. Compared to LPNs loaded with either silibinin or cryptotanshinone alone, S/C-pW-LPNs dramatically slowed tumor progression in 4T1 tumor-bearing nude mice. S/C-pW-LPNs presented with the most robust anti-metastasis activity on smooth lung surfaces and mitigated lung metastasis foci. They also downregulated tumor microenvironment biomarkers such as CD31, TGF-β1, and MMP-9 that promote metastasis. CONCLUSIONS: Silibinin- and cryptotanshinone-co-loaded pW-LPNs efficiently penetrate intestinal barriers, thereby enhancing the oral bioavailability of the drug loads. These nanoparticles exhibit favorable anti-metastasis effects in breast cancer-bearing nude mice. Hence, S/C-pW-LPNs are promising oral drug nanocarriers that inhibit breast cancer lung metastasis. BioMed Central 2020-05-30 /pmc/articles/PMC7260741/ /pubmed/32473632 http://dx.doi.org/10.1186/s12951-020-00638-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Ying
Xie, Xingmei
Hou, Xuefeng
Shen, Junyi
Shi, Jiangpei
Chen, Haizhen
He, Yuanzhi
Wang, Zhi
Feng, Nianping
Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
title Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
title_full Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
title_fullStr Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
title_full_unstemmed Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
title_short Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
title_sort functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260741/
https://www.ncbi.nlm.nih.gov/pubmed/32473632
http://dx.doi.org/10.1186/s12951-020-00638-x
work_keys_str_mv AT liuying functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT xiexingmei functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT houxuefeng functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT shenjunyi functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT shijiangpei functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT chenhaizhen functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT heyuanzhi functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT wangzhi functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis
AT fengnianping functionaloralnanoparticlesfordeliveringsilibininandcryptotanshinoneagainstbreastcancerlungmetastasis